Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 295

1.

After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?

Sculpher M, Palmer S.

Pharmacoeconomics. 2020 Jan 13. doi: 10.1007/s40273-019-00882-6. [Epub ahead of print]

PMID:
31930460
2.

The HOME Study: study protocol for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the time spent in hospital by older acute hospital inpatients.

Walker J, Burke K, Toynbee M, van Niekerk M, Frost C, Magill N, Walker S, Sculpher M, White IR, Sharpe M.

Trials. 2019 Aug 7;20(1):483. doi: 10.1186/s13063-019-3502-5.

3.

Cost-per-diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis.

Phillips AN, Cambiano V, Nakagawa F, Bansi-Matharu L, Wilson D, Jani I, Apollo T, Sculpher M, Hallett T, Kerr C, van Oosterhout JJ, Eaton JW, Estill J, Williams B, Doi N, Cowan F, Keiser O, Ford D, Hatzold K, Barnabas R, Ayles H, Meyer-Rath G, Nelson L, Johnson C, Baggaley R, Fakoya A, Jahn A, Revill P.

J Int AIDS Soc. 2019 Jul;22(7):e25325. doi: 10.1002/jia2.25325.

4.

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ.

Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14.

5.

Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers.

Walker S, Griffin S, Asaria M, Tsuchiya A, Sculpher M.

Appl Health Econ Health Policy. 2019 Oct;17(5):577-590. doi: 10.1007/s40258-019-00481-8.

6.

Adherence to the iDSI reference case among published cost-per-DALY averted studies.

Emerson J, Panzer A, Cohen JT, Chalkidou K, Teerawattananon Y, Sculpher M, Wilkinson T, Walker D, Neumann PJ, Kim DD.

PLoS One. 2019 May 1;14(5):e0205633. doi: 10.1371/journal.pone.0205633. eCollection 2019.

7.

Future Directions for Cost-effectiveness Analyses in Health and Medicine.

Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, Owens DK, Meltzer DO, Kuntz KM, Krahn M, Feeny D, Basu A, Russell LB, Siegel JE, Ganiats TG, Sanders GD.

Med Decis Making. 2018 Oct;38(7):767-777. doi: 10.1177/0272989X18798833.

PMID:
30248277
8.

Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.

Brown LC, Ahmed HU, Faria R, El-Shater Bosaily A, Gabe R, Kaplan RS, Parmar M, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham A, Oldroyd R, Parker C, Bott S, Burns-Cox N, Dudderidge T, Ghei M, Henderson A, Persad R, Rosario DJ, Shergill I, Winkler M, Soares M, Spackman E, Sculpher M, Emberton M.

Health Technol Assess. 2018 Jul;22(39):1-176. doi: 10.3310/hta22390.

9.

Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial: Percutaneous Coronary Intervention for Ischemic Cardiomyopathy.

Perera D, Clayton T, Petrie MC, Greenwood JP, O'Kane PD, Evans R, Sculpher M, Mcdonagh T, Gershlick A, de Belder M, Redwood S, Carr-White G, Marber M; REVIVED investigators.

JACC Heart Fail. 2018 Jun;6(6):517-526. doi: 10.1016/j.jchf.2018.01.024.

10.

Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms.

Ciani O, Epstein D, Rothery C, Taylor RS, Sculpher M.

Cost Eff Resour Alloc. 2018 Apr 16;16:15. doi: 10.1186/s12962-018-0098-7. eCollection 2018.

11.

The Use of MCDA in HTA: Great Potential, but More Effort Needed.

Marsh KD, Sculpher M, Caro JJ, Tervonen T.

Value Health. 2018 Apr;21(4):394-397. doi: 10.1016/j.jval.2017.10.001. Epub 2017 Nov 22.

12.

Supporting the development of a health benefits package in Malawi.

Ochalek J, Revill P, Manthalu G, McGuire F, Nkhoma D, Rollinger A, Sculpher M, Claxton K.

BMJ Glob Health. 2018 Apr 9;3(2):e000607. doi: 10.1136/bmjgh-2017-000607. eCollection 2018.

13.

Quantifying patient centered outcomes associated with the use of bilateral endobronchial coil treatment in patients with severe emphysema.

Evans R, Brutsche M, Busca R, Deslee G, de Soyza A, Fellrath JM, Franzen D, Hartman J, Mealing S, Morton T, Munavvar M, Sculpher M, Shah P, Slebos DJ, Durand-Zaleski I.

Curr Med Res Opin. 2018 Nov;34(11):1927-1932. doi: 10.1080/03007995.2018.1462784. Epub 2018 May 8.

PMID:
29625529
14.

Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment.

Soares MO, Walker S, Palmer SJ, Sculpher MJ.

Med Decis Making. 2018 May;38(4):495-508. doi: 10.1177/0272989X17749829. Epub 2018 Mar 13.

15.

Economic analysis of service and delivery interventions in health care.

Sutton M, Garfield-Birkbeck S, Martin G, Meacock R, Morris S, Sculpher M, Street A, Watson SI, Lilford RJ.

Southampton (UK): NIHR Journals Library; 2018 Feb.

16.

ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.

Sculpher M.

Value Health. 2018 Feb;21(2):171-172. doi: 10.1016/j.jval.2017.12.003. No abstract available.

17.

Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31-2.

Faria R, Soares MO, Spackman E, Ahmed HU, Brown LC, Kaplan R, Emberton M, Sculpher MJ.

Eur Urol. 2018 Jun;73(6):e151-e152. doi: 10.1016/j.eururo.2018.02.003. Epub 2018 Feb 17. No abstract available.

18.

Impact of missed treatment opportunities on outcomes in hospitalised patients with heart failure.

Walker S, Spackman E, Conrad N, Emdin CA, Griffin E, Rahimi K, Sculpher M.

Open Heart. 2017 Dec 22;4(2):e000726. doi: 10.1136/openhrt-2017-000726. eCollection 2017.

19.

Reflecting the real value of health care resources in modelling and cost-effectiveness studies-The example of viral load informed differentiated care.

Revill P, Walker S, Cambiano V, Phillips A, Sculpher MJ.

PLoS One. 2018 Jan 2;13(1):e0190283. doi: 10.1371/journal.pone.0190283. eCollection 2018.

20.

Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research.

Spackman E, Hinde S, Bojke L, Payne K, Sculpher M.

Genet Test Mol Biomarkers. 2017 Dec;21(12):705-716. doi: 10.1089/gtmb.2017.0105. Epub 2017 Oct 13. Review.

21.

Social value and individual choice: The value of a choice-based decision-making process in a collectively funded health system.

Espinoza MA, Manca A, Claxton K, Sculpher M.

Health Econ. 2018 Feb;27(2):e28-e40. doi: 10.1002/hec.3559. Epub 2017 Oct 4.

22.

Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).

Faria R, Soares MO, Spackman E, Ahmed HU, Brown LC, Kaplan R, Emberton M, Sculpher MJ.

Eur Urol. 2018 Jan;73(1):23-30. doi: 10.1016/j.eururo.2017.08.018. Epub 2017 Sep 19.

23.

How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework.

Johannesen KM, Claxton K, Sculpher MJ, Wailoo AJ.

Health Econ. 2018 Feb;27(2):e41-e54. doi: 10.1002/hec.3561. Epub 2017 Aug 22.

24.

Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.

Joyce VR, Sun H, Barnett PG, Bansback N, Griffin SC, Bayoumi AM, Anis AH, Sculpher M, Cameron W, Brown ST, Holodniy M, Owens DK.

MDM Policy Pract. 2017 Jul 3;2(2):2381468317716440. doi: 10.1177/2381468317716440. eCollection 2017 Jul-Dec.

25.

Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee.

Woods B, Manca A, Weatherly H, Saramago P, Sideris E, Giannopoulou C, Rice S, Corbett M, Vickers A, Bowes M, MacPherson H, Sculpher M.

PLoS One. 2017 Mar 7;12(3):e0172749. doi: 10.1371/journal.pone.0172749. eCollection 2017. Review.

26.

Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions.

Sculpher M, Claxton K, Pearson SD.

Value Health. 2017 Feb;20(2):234-239. doi: 10.1016/j.jval.2016.11.021.

27.

Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial.

Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M.

Adv Ther. 2017 Mar;34(3):753-764. doi: 10.1007/s12325-016-0471-x. Epub 2017 Feb 15.

28.

Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.

Rothery C, Claxton K, Palmer S, Epstein D, Tarricone R, Sculpher M.

Health Econ. 2017 Feb;26 Suppl 1:109-123. doi: 10.1002/hec.3467.

29.

Acupuncture for chronic pain and depression in primary care: a programme of research.

MacPherson H, Vickers A, Bland M, Torgerson D, Corbett M, Spackman E, Saramago P, Woods B, Weatherly H, Sculpher M, Manca A, Richmond S, Hopton A, Eldred J, Watt I.

Southampton (UK): NIHR Journals Library; 2017 Jan.

30.

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.

Woods B, Revill P, Sculpher M, Claxton K.

Value Health. 2016 Dec;19(8):929-935. doi: 10.1016/j.jval.2016.02.017.

31.

The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought.

Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, Teerawattananon Y, Asfaw E, Lopert R, Culyer AJ, Walker DG.

Value Health. 2016 Dec;19(8):921-928. doi: 10.1016/j.jval.2016.04.015.

32.

The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation.

Farrar D, Simmonds M, Griffin S, Duarte A, Lawlor DA, Sculpher M, Fairley L, Golder S, Tuffnell D, Bland M, Dunne F, Whitelaw D, Wright J, Sheldon TA.

Health Technol Assess. 2016 Nov;20(86):1-348. Review.

33.

Methods for network meta-analysis of continuous outcomes using individual patient data: a case study in acupuncture for chronic pain.

Saramago P, Woods B, Weatherly H, Manca A, Sculpher M, Khan K, Vickers AJ, MacPherson H.

BMC Med Res Methodol. 2016 Oct 6;16(1):131.

34.

Cancer Drugs Fund requires further reform.

Grieve R, Abrams K, Claxton K, Goldacre B, James N, Nicholl J, Parmar M, Parker C, Sekhon JS, Smeeth L, Spiegelhalter D, Sculpher M.

BMJ. 2016 Sep 27;354:i5090. doi: 10.1136/bmj.i5090. No abstract available.

35.

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.

Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG.

JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195. Erratum in: JAMA. 2016 Nov 8;316(18):1924.

PMID:
27623463
36.

Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial.

Greenwood JP, Ripley DP, Berry C, McCann GP, Plein S, Bucciarelli-Ducci C, Dall'Armellina E, Prasad A, Bijsterveld P, Foley JR, Mangion K, Sculpher M, Walker S, Everett CC, Cairns DA, Sharples LD, Brown JM; CE-MARC 2 Investigators.

JAMA. 2016 Sep 13;316(10):1051-60. doi: 10.1001/jama.2016.12680.

37.

Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals.

Faria R, Woods B, Griffin S, Palmer S, Sculpher M, Ryder SD.

Aliment Pharmacol Ther. 2016 Oct;44(8):866-76. doi: 10.1111/apt.13775. Epub 2016 Aug 25.

38.

Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure.

Mealing S, Woods B, Hawkins N, Cowie MR, Plummer CJ, Abraham WT, Beshai JF, Klein H, Sculpher M.

Heart. 2016 Nov 1;102(21):1742-1749. doi: 10.1136/heartjnl-2015-308883. Epub 2016 Jul 13.

39.

The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.

Hinde S, Epstein D, Cook A, Embleton A, Perren T, Sculpher M.

Value Health. 2016 Jun;19(4):431-9. doi: 10.1016/j.jval.2016.01.013. Epub 2016 Mar 24.

40.

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework.

Malone DC, Berg NS, Claxton K, Garrison LP Jr, IJzerman M, Marsh K, Neumann PJ, Sculpher M, Towse A, Uyl-de Groot C, Weinstein MC.

J Clin Oncol. 2016 Aug 20;34(24):2936-7. doi: 10.1200/JCO.2015.64.4328. Epub 2016 Jun 13. No abstract available.

41.

How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants.

Faria R, Walker S, Whyte S, Dixon S, Palmer S, Sculpher M.

Med Decis Making. 2017 Feb;37(2):148-161. doi: 10.1177/0272989X16645577. Epub 2016 Jul 10.

42.

Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER).

Walker S, Asaria M, Manca A, Palmer S, Gale CP, Shah AD, Abrams KR, Crowther M, Timmis A, Hemingway H, Sculpher M.

Eur Heart J Qual Care Clin Outcomes. 2016 Jan 20;2(2):125-140.

43.

Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa.

Phillips AN, Cambiano V, Revill P, Nakagawa F, Lundgren JD, Bansi-Matharu L, Mabugu T, Sculpher M, Garnett G, Staprans S, Becker S, Murungu J, Lewin SR, Deeks SG, Hallett TB.

J Infect Dis. 2016 Jul 1;214(1):73-9. doi: 10.1093/infdis/jiw120. Epub 2016 Mar 30.

44.

Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?

Whyte S, Dixon S, Faria R, Walker S, Palmer S, Sculpher M, Radford S.

Value Health. 2016 Mar-Apr;19(2):138-44. doi: 10.1016/j.jval.2015.12.009. Epub 2016 Mar 7.

45.
46.

Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial.

Oddershede L, Walker S, Stöhr W, Dunn DT, Arenas-Pinto A, Paton NI, Sculpher M; Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team.

Pharmacoeconomics. 2016 Aug;34(8):795-804. doi: 10.1007/s40273-016-0396-x.

PMID:
26966125
47.

Using electronic health records to predict costs and outcomes in stable coronary artery disease.

Asaria M, Walker S, Palmer S, Gale CP, Shah AD, Abrams KR, Crowther M, Manca A, Timmis A, Hemingway H, Sculpher M.

Heart. 2016 May 15;102(10):755-62. doi: 10.1136/heartjnl-2015-308850. Epub 2016 Feb 10.

48.

Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).

Ross Terres JA, Lozano-Ortega G, Kendall R, Sculpher MJ.

BMC Cardiovasc Disord. 2015 Dec 29;15:180. doi: 10.1186/s12872-015-0175-1.

49.

Should the Lambda (λ) Remain Silent?

Haji Ali Afzali H, Karnon J, Sculpher M.

Pharmacoeconomics. 2016 Apr;34(4):323-9. doi: 10.1007/s40273-015-0359-7. No abstract available.

PMID:
26660350
50.

Cost-effectiveness of integrated collaborative care for comorbid major depression in patients with cancer.

Duarte A, Walker J, Walker S, Richardson G, Holm Hansen C, Martin P, Murray G, Sculpher M, Sharpe M.

J Psychosom Res. 2015 Dec;79(6):465-70. doi: 10.1016/j.jpsychores.2015.10.012. Epub 2015 Nov 9.

Supplemental Content

Loading ...
Support Center